
|Videos|January 10, 2022
Expert Discusses How DMT Differs From Other Psychedelic Medicines
Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discusses DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.
Advertisement
Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discussed DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.
She spoke about the benefits of DMT, what the treatment targets are, and early research of the drug.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Novo Nordisk–Eli Lilly GLP-1 Ad Suit
2
Overlooked Coronavirus Protein May Drive Cytokine Storm, Cardiac Injury in Severe COVID-19
3
8 PDUFA Dates to Watch in Fall and Winter 2026
4
FDA Grants Fast Track Designation to ERAS-0015 for Metastatic Pancreatic Cancer
5


































































































